Harnessing Multispecific Nanobody Innovation for Precise CD3 Complex and HBVgp2 Targeting in Liver Cancer
VHH-P528 is a fully humanized multispecific nanobody designed to simultaneously target the CD3 Complex (T Cell Receptor Complex) and the Long surface protein (HBVgp2) of hepatitis B virus. Currently in the Biological Testing stage, this innovative therapeutic candidate combines targeted immunomodulation with viral antigen recognition, providing a compelling approach to address the challenging landscape of liver cancer. By engaging both T cells and virus-related tumor antigens, VHH-P528 is poised to achieve higher selectivity and therapeutic efficacy, highlighting its potential as a next-generation solution for liver cancer patients with virologic factors.
| Candidate | VHH-P528 |
| Target | CD3 Complex (T Cell Receptor Complex) Long surface protein (HBVgp2) |
| Modality | humanized bispecific VHH |
| Indication | Liver Cancer |
Licensing Opportunity
VHH-P528 is available for licensing and collaborative development. We welcome strategic partnerships to accelerate its clinical translation and maximize impact in liver cancer therapeutics.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P528 |
Modality
VHH-P528 is an advanced multispecific nanobody comprising a triparatopic anti-hepatitis B surface antigen heavy chain polypeptide constructed from three tandem variable heavy chain domains, together with an Fc region and an additional antibody arm targeting CD3. As a single-domain antibody, this nanobody format offers superior tissue penetration, high stability, and the ability for modular engineering. Its small molecular size and robust architecture enable efficient access to tumor sites within the liver, overcoming barriers typically faced by conventional antibodies. The modular design enhances antigen engagement and immune cell recruitment, positioning VHH-P528 as a highly adaptable candidate for the complex microenvironment of liver cancer.
Target
CD3 Complex and HBVgp2 are critical molecular targets for liver cancer immunotherapy. The CD3 Complex, a multiprotein T cell receptor complex, is expressed on the surface of T lymphocytes and plays a pivotal role in mediating T cell activation and cytotoxic function. HBVgp2, a surface glycoprotein of hepatitis B virus, is frequently retained on hepatocellular carcinoma cells linked to chronic HBV infection. Both CD3 Complex and HBVgp2 are attractive targets: CD3 Complex enables robust recruitment of adaptive immune responses, while HBVgp2 provides selective viral antigen targeting in liver cancer. By binding both CD3 Complex and HBVgp2, VHH-P528 delivers precise immunotherapeutic activity with strategic value in eradicating HBV-associated malignancies and improving patient outcomes.
Mechanism of Action
VHH-P528 exerts its antitumor effects through dual targeting of CD3 Complex on T lymphocytes and HBVgp2 on liver cancer cells. The nanobody physically bridges T cells to tumor cells by engaging CD3 Complex and the viral envelope antigen HBVgp2, facilitating redirected T cell activation and cytolytic activity against malignant cells expressing viral antigens. This engages tumor-specific immune destruction while interfering with viral entry and persistence. As a nanobody-based platform, VHH-P528 may be further engineered into antibody-drug conjugates, bispecifics, or multivalent constructs, broadening potential applications in oncology and infectious disease. Its modularity underscores versatility and development opportunities for tailored therapies.
Liver Cancer
Liver cancer, primarily hepatocellular carcinoma, remains one of the leading causes of cancer-related mortality worldwide. Global incidence continues to be driven by risk factors such as chronic HBV and HCV infection, alcoholic liver disease, and metabolic syndromes. Standard therapies include surgical resection, locoregional interventions, systemic chemotherapy, and targeted therapy. Despite advances, survival rates remain suboptimal due to late diagnosis, tumor heterogeneity, recurrence, and resistance to existing treatments. There is a critical need for innovative therapies that address both tumor cells and underlying viral etiology. VHH-P528's ability to engage CD3 Complex for T cell activation, while specifically recognizing HBVgp2 expressed on tumor cells, offers a precision medicine approach with the potential to overcome immunosuppression and viral persistence, setting a new standard for liver cancer treatment.